Helix Acquisition to restate financials after reclassifying all public shares as temporary equity

MoonLake Immunotherapeutics

Non-reliance on previously issued financial statements from Oct 2020 through Sep 2021 due to share classification error.
Re-evaluation prompted by SEC comment letter; all public shares now classified as temporary equity.
Restatements to be filed as amendments to Form 10-Q for Q3 2021 and Form 10-K for 2020.
Material weakness in internal control over financial reporting identified; remediation plan to be detailed.
No impact on cash position or trust account established in connection with the IPO.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.